These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Repeated peribulbar injections of triamcinolone acetonide: a successful and safe treatment for moderate to severe Graves' ophthalmopathy. Bordaberry M; Marques DL; Pereira-Lima JC; Marcon IM; Schmid H Acta Ophthalmol; 2009 Feb; 87(1):58-64. PubMed ID: 18937809 [TBL] [Abstract][Full Text] [Related]
5. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501 [TBL] [Abstract][Full Text] [Related]
6. Retrobulbar injection of triamcinolone in thyroid associated orbitopathy. Poonyathalang A; Preechawat P; Charoenkul W; Tangtrakul P J Med Assoc Thai; 2005 Mar; 88(3):345-9. PubMed ID: 15962642 [TBL] [Abstract][Full Text] [Related]
7. Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections. Lee SJ; Rim TH; Jang SY; Kim CY; Shin DY; Lee EJ; Lee SY; Yoon JS Graefes Arch Clin Exp Ophthalmol; 2013 Jan; 251(1):261-70. PubMed ID: 22968823 [TBL] [Abstract][Full Text] [Related]
8. Role of methotrexate in thyroid-related orbitopathy. Rubinov A; Zommer H; Aghazadeh H; Weis E Can J Ophthalmol; 2018 Feb; 53(1):34-38. PubMed ID: 29426438 [TBL] [Abstract][Full Text] [Related]
9. Subconjunctival injection of triamcinolone for the treatment of upper lid retraction associated with thyroid eye disease. Lee JM; Lee H; Park M; Baek S J Craniofac Surg; 2012 Nov; 23(6):1755-8. PubMed ID: 23147303 [TBL] [Abstract][Full Text] [Related]
10. Triamcinolone for the Treatment of Graves Ophthalmopathy Tested With Short Tau Inversion Recovery Magnetic Resonance. Ortiz-Basso T; Vigo RL; Sidelnik M; Vazquez-Durand MS; Shokida MF; Prémoli EJ; García-Mónaco R Ophthalmic Plast Reconstr Surg; 2019; 35(1):22-24. PubMed ID: 29923962 [TBL] [Abstract][Full Text] [Related]
11. Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy. Xu D; Liu Y; Xu H; Li H Can J Ophthalmol; 2012 Feb; 47(1):34-41. PubMed ID: 22333849 [TBL] [Abstract][Full Text] [Related]
12. Teprotumumab for the Treatment of Active Thyroid Eye Disease. Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679 [TBL] [Abstract][Full Text] [Related]
13. 99mTc-DTPA SPECT/CT provided guide on triamcinolone therapy in Graves' ophthalmopathy patients. Liu D; Xu X; Wang S; Jiang C; Li X; Tan J; Deng Z Int Ophthalmol; 2020 Mar; 40(3):553-561. PubMed ID: 31792849 [TBL] [Abstract][Full Text] [Related]
14. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM; Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246 [TBL] [Abstract][Full Text] [Related]
16. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699 [TBL] [Abstract][Full Text] [Related]
17. [Pathological changes after periocular injection of triamcinolone and hyaluronidase in guinea pigs]. Cheng L; Wang Q; Lei S; He WM Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 43(5):690-3. PubMed ID: 23230740 [TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Stan MN; Garrity JA; Carranza Leon BG; Prabin T; Bradley EA; Bahn RS J Clin Endocrinol Metab; 2015 Feb; 100(2):432-41. PubMed ID: 25343233 [TBL] [Abstract][Full Text] [Related]
19. A pilot study on the use of prednisolone-encapsulated liposomes for the treatment of moderate-to-severe Graves' orbitopathy with reduced systemic steroid exposure. Detiger SE; Kremer TM; A S H Dalm V; de Keizer ROB; Wubbels RJ; Metselaar JM; van Hagen PM; Peeters RP; Paridaens D Acta Ophthalmol; 2021 Nov; 99(7):797-804. PubMed ID: 33423386 [TBL] [Abstract][Full Text] [Related]
20. Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy. Alkawas AA; Hussein AM; Shahien EA Clin Exp Ophthalmol; 2010 Oct; 38(7):692-7. PubMed ID: 20497432 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]